A Phase 1/2 interventional study of Peanut powder and Peanut extract in Peanut Hypersensitivity, Food Hypersensitivity and Immediate Hypersensitivity, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing peanut in Peanut Hypersensitivity — none open to participants now, 1 under way, none of them phase 3. peanut · Peanut Hypersensitivity.
Among the 13 studies testing peanut in Peanut Hypersensitivity, this one is the 6th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 1/2, and was the 4th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →None of the 13 studies testing peanut in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 6 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10
First in 2008; this study’s year is marked. 2 started in 2010.
This study's enrollment of 21 is below the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 20 across the 13 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 8 most frequent:
Johns Hopkins University is the lead sponsor of 1,816 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 7 studies filed under Peanut Hypersensitivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing peanut in Peanut Hypersensitivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.
To effectively address the Primary Objectives of this pilot study, 30 subjects aged 6-21 years with: (1) a convincing clinical history of peanut allergy (PA), (2) a serum immunoglobulin E (IgE) specific to peanut of >0.35 kilo units per liter (kU/L) and a skin prick test (SPT) wheal >3 mm, will be enrolled. Subjects will be recruited from the Johns Hopkins Pediatric Allergy Clinic.
Participants will undergo an initial screening visit that will include a medical history, physical exam, skin testing, and phlebotomy. Informed consent and assent will be obtained. At the next two visits, 20 participants will complete a double-blind placebo-controlled food challenge (DBPCFC). Eligible subjects will be randomized in a 1:1 ratio into two groups. One group will receive active SLIT with placebo OIT and the other group will begin active OIT with placebo SLIT dose escalation. Over the next 16 weeks of the study, subjects will undergo SLIT and OIT dose increases. A maintenance dose will then be taken at home daily for 12 months. A DBPCFC will be completed after 6 months and 12 months of home dosing. Those patients who pass the DBPCFC will be taken off SLIT and OIT for 4 weeks. A final challenge will be administered at the end of this period.
Ten additional peanut-allergic subjects age 6-21 years will be enrolled and followed as longitudinal controls for the mechanistic studies. These subjects will follow a modified schedule compared to those subjects receiving study treatment and will be evaluated by phlebotomy, end point titration prick skin testing, and saliva collection. These patients will continue strict avoidance of peanut unless otherwise advised by their personal physician.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of steroid medications (oral steroids, such as prednisone or Medrol, steroid injections, such as Kenalog, or IV or oral corticosteroid burst) in the following manners:
o History of daily oral steroid dosing within 4 weeks prior to baseline visit or for > 1 month during the past year or burst oral steroid course in the past 6 months or > 1 burst oral steroid course in the past year.
Asthma requiring
Severe reaction at initial DBPCFC, defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These subjects will receive peanut powder given orally and placebo extract given sublingually.
Drug: Peanut powder · Drug: Placebo extract
These subjects will receive peanut extract given sublingually and placebo powder given orally.
Drug: Peanut extract · Drug: Placebo powder
Delivered orally
Delivered sublingually
Delivered sublingually
Delivered orally
Number of Participants With Induced Peanut Desensitization at 12 Months
Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.
Time frame: 12 months
Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)
Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)
Time frame: Baseline and end of dose build-up (up to 16 weeks)
Between Arm Change in IgG4 From Baseline to 6 Months
IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months
Time frame: Baseline and 6 months
Between Arm Change in IgG4 From Baseline to 12 Months
IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months
Time frame: Baseline and 12 months
Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)
Time frame: Baseline to end of dose build-up (up to 16 weeks)
Between Arm Change in IgE From Baseline to 6 Months
Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months
Time frame: Baseline and 6 months
Between Arm Change in IgE From Baseline to 12 Months
IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months
Time frame: Baseline and 12 months
| Milestone | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Started | 10 | 11 |
| Completed | 9 | 7 |
| Not completed | 1 | 4 |
| Withdrew: Gastrointestinal symptoms | 1 | 1 |
| Withdrew: Eosinophilic esophagitis | 0 | 1 |
| Withdrew: Anaphylaxis | 0 | 1 |
| Withdrew: Participant noncompliance | 0 | 1 |
Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.
| Participants | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Number of Participants With Induced Peanut Desensitization at 12 Months | 9 | 7 |
Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)
| mga/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 0.9 (0.19 to 1.76) | 1.3 (0.22 to 5.89) |
| End of dose build-up (up to 16 weeks) | 2.5 (0.47 to 7.07) | 11.3 (0.99 to 58.7) |
IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months
| mga/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 0.9 (0.19 to 1.76) | 1.3 (0.22 to 5.89) |
| 6 months | 7.9 (1.51 to 76.2) | 83.4 (21.2 to 677) |
IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months
| mga/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 0.9 (0.19 to 1.76) | 1.3 (0.22 to 5.89) |
| 12 months | 8.5 (2.42 to 69.1) | 76 (28.8 to 1790) |
| kUa/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 163 (37.5 to 746) | 169 (35.1 to 716) |
| End of dose build-up (up to 16 weeks) | 369 (47.4 to 1960) | 392 (84 to 1069) |
Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months
| kUa/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 163 (37.5 to 746) | 169 (35.1 to 716) |
| 6 months | 387 (34.1 to 1032) | 68 (50.9 to 204) |
IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months
| kUa/L | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Baseline | 163 (37.5 to 746) | 169 (35.1 to 716) |
| 12 months | 273 (21.0 to 1111) | 53 (32.4 to 82.9) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active SLIT/Placebo OIT | 0/4,578 (0%) | 0/4,578 (0%) | 416/4,578 (9.1%) |
| Active OIT/Placebo SLIT | 0/4,049 (0%) | 0/4,049 (0%) | 1,736/4,049 (42.9%) |
| Event | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT |
|---|---|---|
| Gastrointestinal symptomsGastrointestinal disorders | 325/4578 | 1344/4049 |
| Respiratory SymptomsRespiratory, thoracic and mediastinal disorders | 27/4578 | 279/4049 |
| skin symptomsSkin and subcutaneous tissue disorders | 64/4578 | 113/4049 |
| Age, Categorical(Participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| <=18 years | 10 | 11 | 21 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 4 | 7 | 11 |
| Region of Enrollment(participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| United States | 10 | 11 | 21 |
| Prior history of peanut anaphylaxis(Participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| Count of participants | 1 | 6 | 7 |
| Other food allergies(Participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| Count of participants | 10 | 10 | 20 |
| Atopic dermatitis(Participants) | Active SLIT/Placebo OIT | Active OIT/Placebo SLIT | Total |
|---|---|---|---|
| Count of participants | 6 | 6 | 12 |
Plan to share: No
The record gives a start of Mar 2010, a primary completion of Jan 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peanut